Pre-made Talizumab benchmark antibody (Whole mAb, anti-IGHE/IgE therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-1005

Anti-IGHE/IgE therapeutic antibody (Pre-made Talizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Talizumab (TNX-91) is a humanized monoclonal antibody that was under development by Tanox in Houston, Texas as a new-concept therapeutic for allergic diseases. The unique anti-IgE antibody was designed to target immunoglobulin E (IgE) and IgE-expressing B lymphocytes specifically, without binding to IgE already bound by the high affinity IgE receptors on mast cells and basophils. Talizumab was tested in clinical trials at National Jewish Medical and Research Center and other medical centers and allergy clinics across the U. S. and shown to be able to prevent allergic reactions to accidental exposure to peanuts, which is contained in many kinds of foods.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-1005-1mg 1mg 3090
GMP-Bios-INN-1005-10mg 10mg Inquiry
GMP-Bios-INN-1005-100mg 100mg Inquiry
GMP-Bios-INN-1005-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Talizumab Biosimilar, Whole Mab: Anti-Ighe/IgE therapeutic antibody
INN Name Talizumab
FormatWhole mAb
Species Reactivityhuman
CH1 IsotypeIgG1 - nd
VD LCIgG1 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesMRC Technology (London UK) / Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Tanox Inc. (Houston TX USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0